alendronate has been researched along with Hyperparathyroidism in 13 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism." | 7.71 | Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. ( Blackwell, PJ; Fairbairn, KJ; Hosking, DJ; Parker, CR, 2002) |
| "Galactosylhydroxylysine appears to be a sensitive index of bone resorption, useful in the clinical assessment of bone involvement and in the management of patients with mild primary hyperparathyroidism." | 7.69 | Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. ( Bertoldo, F; Bettica, P; Braga, V; LoCascio, V; Moro, L; Pasini, AF; Stefani, L, 1994) |
| ") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women." | 7.69 | Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994) |
| "Treatment with alendronate over 2 yr was associated with a significant (6." | 6.71 | Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. ( Ahmed, MM; Bilezikian, JP; Dubois, SJ; Ho, AY; Khan, AA; Kung, AW; Rubin, MR; Schussheim, D; Shaikh, AM; Silverberg, SJ; Standish, TI; Syed, Z; Syed, ZA, 2004) |
| "We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism." | 3.71 | Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. ( Blackwell, PJ; Fairbairn, KJ; Hosking, DJ; Parker, CR, 2002) |
| "Galactosylhydroxylysine appears to be a sensitive index of bone resorption, useful in the clinical assessment of bone involvement and in the management of patients with mild primary hyperparathyroidism." | 3.69 | Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. ( Bertoldo, F; Bettica, P; Braga, V; LoCascio, V; Moro, L; Pasini, AF; Stefani, L, 1994) |
| ") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women." | 3.69 | Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994) |
| "For subjects with postmenopausal osteoporosis, receiver-operating characteristic curve analysis yielded areas under the curve of 0." | 2.70 | Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. ( Baylink, D; Drinkwater, B; Farley, S; Kleerekoper, M; Lang, R; Lappe, J; Licata, A; McClung, M; Miller, P; Nattrass, S; Powell, H; Recker, R; Sarno, L; Sarno, M; Schwartz, EN; Tjersland, G; Tucci, JR; Warnick, GR; Wolf, S, 2001) |
| "The early inhibition of bone resorption induces a reduction in serum calcium which leads to increased parathyroid hormone (PTH), and subsequently an increase in 1,25-dihydroxyvitamin D." | 2.41 | Bisphosphonates: an overview with special reference to alendronate. ( Vasikaran, SD, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohishi, M | 1 |
| Chiusaroli, R | 1 |
| Ominsky, M | 1 |
| Asuncion, F | 1 |
| Thomas, C | 1 |
| Khatri, R | 1 |
| Kostenuik, P | 1 |
| Schipani, E | 1 |
| Yamamoto, S | 1 |
| Suzuki, A | 1 |
| Sasaki, H | 1 |
| Sekiguchi-Ueda, S | 1 |
| Asano, S | 1 |
| Shibata, M | 1 |
| Hayakawa, N | 1 |
| Hashimoto, S | 1 |
| Hoshinaga, K | 1 |
| Itoh, M | 1 |
| Parker, CR | 1 |
| Blackwell, PJ | 1 |
| Fairbairn, KJ | 1 |
| Hosking, DJ | 1 |
| Chow, CC | 1 |
| Chan, WB | 1 |
| Li, JK | 1 |
| Chan, NN | 1 |
| Chan, MH | 1 |
| Ko, GT | 1 |
| Lo, KW | 1 |
| Cockram, CS | 1 |
| Khan, AA | 1 |
| Bilezikian, JP | 1 |
| Kung, AW | 1 |
| Ahmed, MM | 1 |
| Dubois, SJ | 1 |
| Ho, AY | 1 |
| Schussheim, D | 1 |
| Rubin, MR | 1 |
| Shaikh, AM | 1 |
| Silverberg, SJ | 1 |
| Standish, TI | 1 |
| Syed, Z | 1 |
| Syed, ZA | 1 |
| Makras, P | 1 |
| Kaltsas, GA | 1 |
| Athanasoulis, T | 1 |
| Papadogias, D | 1 |
| Zografos, GN | 1 |
| Kontogeorgos, G | 1 |
| Borboli, N | 1 |
| Piaditis, G | 1 |
| LoCascio, V | 2 |
| Braga, V | 2 |
| Bertoldo, F | 2 |
| Bettica, P | 1 |
| Pasini, AF | 1 |
| Stefani, L | 1 |
| Moro, L | 1 |
| Adami, S | 2 |
| Zamberlan, N | 1 |
| Mian, M | 1 |
| Dorizzi, R | 1 |
| Rossini, M | 2 |
| Braga, B | 1 |
| Gatti, D | 2 |
| Rodan, GA | 1 |
| Seedor, JG | 1 |
| Balena, R | 1 |
| Bonde, M | 1 |
| Garnero, P | 1 |
| Fledelius, C | 1 |
| Qvist, P | 1 |
| Delmas, PD | 1 |
| Christiansen, C | 1 |
| Isaia, G | 1 |
| Sartori, L | 1 |
| Sarno, M | 1 |
| Sarno, L | 1 |
| Baylink, D | 1 |
| Drinkwater, B | 1 |
| Farley, S | 1 |
| Kleerekoper, M | 1 |
| Lang, R | 1 |
| Lappe, J | 1 |
| Licata, A | 1 |
| McClung, M | 1 |
| Miller, P | 1 |
| Nattrass, S | 1 |
| Recker, R | 1 |
| Schwartz, EN | 1 |
| Tucci, JR | 1 |
| Wolf, S | 1 |
| Powell, H | 1 |
| Tjersland, G | 1 |
| Warnick, GR | 1 |
| Vasikaran, SD | 1 |
2 reviews available for alendronate and Hyperparathyroidism
| Article | Year |
|---|---|
Preclinical pharmacology of alendronate.
Topics: Alendronate; Animals; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Estrogens; | 1993 |
Bisphosphonates: an overview with special reference to alendronate.
Topics: Alendronate; Bone Density; Bone Neoplasms; Bone Resorption; Calcium; Clinical Trials as Topic; Dipho | 2001 |
5 trials available for alendronate and Hyperparathyroidism
| Article | Year |
|---|---|
Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease.
Topics: Adult; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Remodeling; Collage | 2013 |
Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism.
Topics: Administration, Oral; Aged; Alendronate; Biomarkers; Bone Density; Calcium; Female; Follow-Up Studie | 2003 |
Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; | 2004 |
Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Alkaline Phospha | 2001 |
Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease.
Topics: Adult; Aged; Alendronate; Amino Acids; Area Under Curve; Biomarkers; Bone Diseases, Metabolic; Cross | 2001 |
6 other studies available for alendronate and Hyperparathyroidism
| Article | Year |
|---|---|
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Dise | 2009 |
Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Calcium; Creatinine; Female; Humans; Hydroxyproli | 2002 |
Treatment with oral biphosphonates can increase the sensitivity of sestamibi radionuclide imaging in patients with primary hyperparathyroidism.
Topics: Adenoma; Aged; Alendronate; Calcium; Female; Humans; Hyperparathyroidism; Hyperplasia; Male; Middle | 2005 |
Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism.
Topics: Aged; Alendronate; Biomarkers; Bone Resorption; Diphosphonates; Female; Humans; Hydroxylysine; Hydro | 1994 |
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Diseases, Metabolic; Bone Resorption; Calcium; Diphosp | 1994 |
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen | 1997 |